Sumatriptan-naproxen sodium in migraine: A review

European Journal of Neurology 2024 Sep:31 Suppl 2:e16434. doi: 10.1111/ene.16434. Robyn-Jenia Wilcha, Shazia K Afridi , Piero Barbanti, Hans Christoph Diener, Tim Patrick Jürgens, Michel Lanteri-Minet, Christian Lucas, Jerôme Mawet, Xavier Moisset, Antonio Russo, Simona Sacco, Alexandra J Sinclair, Marja-Liisa Sumelahti , Cristina Tassorelli, Peter J Goadsby  Abstract Background: Varied responses to acute migraine medications

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial

JAMA Neurology 2024 Sep 16:e243043. doi: 10.1001/jamaneurol.2024.3043. Online ahead of print. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil , Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Yiping Yang, Gabriel Paiva da Silva Lima  Abstract Importance: Patients with chronic migraine and medication

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study

Cephalalgia 2024 Aug;44(8):3331024241274343.  doi: 10.1177/03331024241274343. Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton Abstract Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology. Methods: This cross-sectional, web-based

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study

The journal of headache and pain 2024 Aug 19;25(1):134. doi: 10.1186/s10194-024-01834-y. Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C Buse Abstract Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

Neurology 2024 Jul 23;103(2):e209584.  doi: 10.1212/WNL.0000000000209584. Epub 2024 Jun 26. Peter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, Genevieve Demarquay, Sait Ashina, Fumihiko Sakai, Brian Neel, Pranav Gandhi , Brett Dabruzzo, Jonathan H Smith, Yingyi Liu, Joel M Trugman Abstract Background and objectives: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Neurology 2024 May;102(10):e209349.  doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet    Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab

Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin